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Abstract There is no clear international consensus
regarding the optimal medication therapy for treating
Wilson’s disease (WD). This study systematically reviews
the effectiveness of various medication therapies in com-
mon use, specifically focusing on preliminary findings
concerning the combination of a chelating agent and zinc.
A systematic PubMed search was executed to locate orig-
inal studies on the effectiveness of commonly used medi-
cations for WD published between January 1989 and
August 2014. The results were used to conduct a systematic
review of studies on combination therapies. A total of 17
combination therapy studies involving 1056 patients were
reviewed. These were analyzed in terms of data on effec-
tiveness, adverse effects, and mortality. Results from a
pooled analysis indicate that combination therapies for
hepatic patients were significantly less effective than the
same therapies for neurological manifestations (47.1 vs.
78.6 %; pooled relative risk ratio (RR): 0.63, 95 % confi-
dence interval CI 0.43–0.94; p = 0.02). Data from a sub-
group analysis show that the combination therapy of
penicillamine plus zinc sulfate resulted in a significantly
higher mortality rate compared to all other combination
therapy types (16.3 vs. 4.7 %; RR: 3.51, 95 % CI 1.54–8.00;
p\ 0.001). The use of combination therapies involving zinc
and a chelator should be carefully monitored with close
clinical observations and frequent biochemical tests, espe-
cially for WD patients with hepatic manifestations.
Keywords Biomedical informatics  Wilson’s disease 
Combination therapy  Effectiveness  Safety
1 Introduction
Wilson’s disease (WD) (also known as hepatolenticular
degeneration, or HLD) is a rare inherited autosomal
recessive disorder associated with mutations in the ade-
nosine triphosphatase 7B (ATP7B) gene [1–18] and char-
acterized by copper metabolic abnormalities [19, 20].
Excessive copper accumulation can result in toxicity and
damage to the brain, liver, kidney, and other tissues. WD
has a broad spectrum of clinical presentations, with hepatic
and neurological symptoms considered the main features
[21]. While liver transplants (LTs) and gene therapies are
provided to a small number of WD patients, the large
majority require lifelong medication to control the
absorption and storage of copper in their bodies. The most
commonly used drugs are penicillamine (DPA) [22], tri-
entine (TETA) [23], zinc salts (Zn) [24, 25], and
tetrathiomolybdate (TM; an experimental therapy that is
not yet commercially available) [26, 27]. The goal of
medication is to prevent, stabilize, or reverse copper
overload and WD symptoms [28].
The European Association for the Study of the Liver
(EASL) [19] and the American Association for the Study
of Liver Diseases (AASLD) [20] announced their respec-
tive clinical practice guidelines for WD in 2012 and 2008,
but no clear international consensus exists regarding an
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optimal medication therapy. One reason is the diversity of
WD genotypes and phenotypes, which makes it difficult to
determine differences in drug effectiveness. Another
challenge is the small number of known cases, with a
worldwide prevalence of 1/30,000 [18]. This makes it
difficult to conduct large-scale cohort randomized clinical
trials. Our motivations were to collect and compile avail-
able data from past studies on the effectiveness and safety
of commonly used WD medications, and to review original
studies found in the PubMed database.
In combination therapies for WD, zinc and a chelating
agent (chelator) are utilized to block copper uptake and to
eliminate excess copper [16]. The two medications must be
taken at least 1 hour apart in order to mitigate zinc
chelation [14]. They are still considered controversial, with
few rigorously designed studies and little in the way of
safety data [29]. The most frequently cited studies that
suggest favorable outcomes for combination therapy using
DPA plus zinc or TETA plus zinc [29] are those by Dha-
wan et al. [30], Askari et al. [31], and Santos Silva et al.
[32]. However, some earlier studies [33, 34] reported no
advantages for the DPA-zinc combination. Both EASL
[19] and AASLD [20] assert that considerably more
research is required to determine whether combination
therapy using a chelator plus zinc has advantages for WD
patients. Therefore, our primary goal was to verify whether
combination therapies are effective and safe at statistically
significant levels for patients with different clinical
presentations.
2 Materials and Methods
2.1 Search Strategy and Study Selection
We performed a systematic search of the National Center
for Biotechnology Information’s PubMed database [35] for
original WD treatment studies published between January
1989 and August 2014. Search keywords were ‘‘Wilson’s
disease’’ or its synonyms (including ‘‘HLD’’), and at least
one of the most commonly used drugs: ‘‘penicillamine,’’
‘‘trientine,’’ ‘‘zinc,’’ ‘‘tetrathiomolybdate’’, and their brand
names, acronyms, abbreviations, and synonyms. Inclusion
criteria included prospective, retrospective, randomized,
and non-randomized controlled studies with human sub-
jects published as full articles written in English or Chi-
nese. Exclusion criteria included animal studies, case
reports or case series, reviews, letters, short papers, edito-
rials, metal metabolism or pharmacological research,
diagnostic or other testing studies, liver transplants or other
non-medication treatments, duplicate reports, and insuffi-
cient data. Date of last search: September 1, 2014.
2.2 Definition of WD Phenotypes
Four phenotype presentation categories were noted: neu-
rological, hepatic, mixed, and asymptomatic. Following the
lead of Ferenci et al. [36], patients with neurological and/or
psychiatric symptoms at diagnosis were classified as neu-
rological. The definition of hepatic presentation required
the exclusion of neurological symptoms noted during a
detailed examination at the time of diagnosis [36]. Pure
hematological abnormalities such as Coombs negative
hemolytic anemia were classified as hepatic. Asymp-
tomatic manifestations included asymptomatic and pre-
symptomatic presentation. Finally, patients with other
miscellaneous symptoms (e.g., renal dysfunction and bone
deformities) were placed in a mixed presentation category
with patients showing simultaneous hepatic and neu-
ropsychiatric symptoms.
2.3 Treatment Effect Definition
To maintain consistency, we used a comparative unit called
‘‘treatment block’’ (TB) [16] to calculate the frequencies of
adverse effects and treatment effectiveness for patients dur-
ing specific time durations. One TB equaled the duration of
one therapy up to the time that a medication was changed, or
until the end of the follow-up period [16]. For our purposes, a
TB was considered effective when the author of a research
paper used terms such as ‘‘effective,’’ ‘‘efficacious,’’ ‘‘suc-
cessful,’’ ‘‘improved,’’ ‘‘stable,’’ ‘‘normal,’’ ‘‘biochemically
improved,’’ ‘‘responsive,’’ ‘‘non-progressive’’, or their syn-
onyms. The list of terms indicating non-effectiveness inclu-
ded ‘‘ineffective,’’ ‘‘inefficacious,’’ ‘‘failed,’’ ‘‘deteriorated,’’
‘‘worsened,’’ ‘‘degenerated,’’ ‘‘abnormal,’’ ‘‘severe side
effects,’’ ‘‘LT,’’ ‘‘dead,’’ ‘‘treatment failure,’’ ‘‘stationary,’’
‘‘unchanged,’’ ‘‘clinical suspicion,’’ ‘‘progressive,’’ ‘‘non-
responsive’’, or their synonyms.
2.4 Data Extraction
To select studies according to our inclusion and exclusion
criteria, two authors initially screened the entry informa-
tion, titles, and abstracts of all retrieved records. Next, full
texts were scanned to determine conformance with the
criteria. Two authors independently extracted data and
outcomes using a standardized form. All disagreements
were discussed with a third author. Studies were included
and data extracted in cases where a consensus was
achieved. Other extracted information included first author,
country, publication year, number of patients, patient
gender ratio, patient phenotype ratio, adverse effects, and
mortality (liver transplant and deceased counts).
698 J.-C. Chen et al.
123
2.5 Statistical Analyses
All analyses were performed using Cochrane RevMan 5.3
and SPSS Statistics 22.0. Pooled relative risk ratios (RRs)
and 95 % confidence intervals (CIs) were calculated from
the original study data using the Mantel–Haenszel method
with a random-effects model. A fixed-effects model was
selected for cases with low heterogeneity (I2\ 30 %). The
Mantel–Haenszel method generates estimates of associa-
tions between exposures and outcomes after accounting for
confounding effects. We stratified the data into two or
more confounding factor levels before computing pooled
RRs across the strata. Note that the random-effects model
has a stricter assumption than the fixed-effects model. We
used the random-effects model to achieve conservative RR
and CI estimates.












where aj, bj, cj, and dj are the numbers of patients in each
cell of a two-by-two table in the j-th stratum of the con-
founding variable, nj represents the number of patients in
the j-th stratum, and m is the total number of strata.
Correlations and associations between discrete values of
nominal data variables from different treatment groups
were evaluated using a Pearson Chi square (v2) test and Phi
or Cramer’s V measures. We used Chi square tests to
determine the likelihood of independence between effec-
tiveness/safety and different medications/phenotypes. A
rejected null hypothesis suggested some degree of corre-
lation between the two variables. To obtain measures of
association between those variables, Phi or Cramer’s V
values were calculated using a value of between 0 and 1. A
measure of association achieved a maximum numerical
value of 1 when the two variables had a perfect relationship
with each other, and a value of 0 when there was no
relationship. After the observed measure of association
values had been calculated, if the measure was significantly
different from 0, it was viewed as showing a significant
relationship between the two variables. A p value of\0.05
was considered statistically significant.
3 Results
3.1 Included Literature
A total of 916 hits were screened, 139 of which were
excluded because they were written in languages other than
English or Chinese. Another 480 studies were excluded
during the secondary selection process of reading the
retrieved titles and abstracts, and 245 were excluded during
the tertiary step of scanning the full texts of potentially
eligible studies. A total of 50 studies were included for
prevalence investigation, and of these, 17 described out-
comes from combination therapies and were therefore
accepted for this review [1–17]. The study selection pro-
cedure is summarized in Fig. 1, characteristics of the 17
studies are shown in Table 1, and mean follow-up times
and outcomes regarding the effectiveness of combination
therapies in each study are shown in Table 2. As shown,
the papers in the final sample discussed seven combina-
tions of a chelator and a zinc salt: (a) DPA ? Zn sulfate,
(b) DPA ? unknown or another Zn salt (e.g., zinc glu-
conate), (c) TETA ? Zn sulfate, (d) TETA ? Zn acetate,
(e) TETA ? unknown or another Zn salt, and (f) unknown
chelator DPA or TETA ? any Zn salt.
916 potenally relevant studies 
idenﬁed and screened for retrieval
139 studies were excluded as in 
language other than English and 
Chinese
194 case reports were 
excluded
87 animal studies were 
excluded
777 studies screened on 
tle/abstract
199 studies were excluded as 
reviews, leers, short papers, or 
editorials
297 studies screened on full text
153 studies were excluded:
65 on metal metabolism or 
pharmacological research
54 on diagnoses, genec assays, 
assessments, or other tests
34 on liver transplantaons or 
other non-medicaon treatments
94 studies were excluded:
55 with data duplicaon, overlap, 
or deﬁciency
39 on dermal lesions, pregnancy, 
other diseases, or the 
experimental tetrathiomolybdate
50 studies included for 
prevalence invesgaon
17 studies on combinaon therapy 
included for this review
Fig. 1 Flow chart of included and excluded studies for this review
Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease 699
123
3.2 Prevalence Investigation
Of the 2954 WD patients mentioned in 45 of the 50 studies
included for the prevalence investigation, 1357 (45.9 %)
were female (95 % CI 44.1–47.7 %). Pooled mean age at
diagnosis as mentioned in 47 of the same 50 papers was
18.7 years, ranging from 6 to 40 years. For our phenotype
prevalence investigation, of the 2988 patients mentioned in
47 of the 50 included studies, those with neurological,
hepatic, mixed, or asymptomatic presentations numbered
1058 (35.4 %), 1242 (41.6 %), 341 (11.4 %), and 347
(11.6 %), respectively. The number of hepatic patients was
approximately 1.2 times that of neurological patients.
When combined with the mixed phenotype, the total
number of hepatic patients (i.e., at least one liver-related
symptom) was 1583 (52.9 % of the total patient sample).
3.3 Effectiveness
Of the 437 pooled TBs shown in Table 2, 264 responded
positively to a combination therapy, for an overall effec-
tiveness rate of 60.4 % (95 % CI 55.8–65.0 %), lower than
the rates reported by Bruha et al. for DPA monotherapy
(73/99, or 73.7 % (95 % CI 65.1–82.4 %)) [15], Weiss
et al. for TETA monotherapy (90/109, or 82.6 % (95 % CI
75.4–89.7 %)) [37], and Weiss et al. for zinc monotherapy
(63/88, or 71.6 % (95 % CI 62.2–81.0 %)) [16]. As shown
in Table 3, results from our inter-study analysis indicate
significant differences in effectiveness rates between
combination therapies and the three monotherapies: an RR
of 0.82 for DPA [15] (95 % CI 0.71–0.94, Fig. 2), an RR of
0.73 for TETA [37] (95 % CI 0.65–0.82, Fig. 3), and an
RR of 0.84 for Zn [16] (95 % CI 0.72–0.98, Fig. 4). In this
part of our study, we used the number of effective TBs as
the number of events.
We then searched for relationships between phenotype
and combination therapy effectiveness, and found that less
than one half (47.1 %, 95 % CI 38.2–56.0 %) of the TBs in
the hepatic group (mixed phenotype excluded) responded
well to combination therapy, compared to 78.6 % (95 % CI
70.7–86.6 %) of TBs in the neurological group (Table 2).
According to our subgroup analyses (two-phenotype
stratification), a statistically significant difference exists
between the two subgroups (p = 0.02) (Fig. 5). The RR of
the overall effectiveness rate was 0.63 (95 % CI
0.43–0.94), indicating that the combination therapies were
31.5 % (95 % CI 18.8–44.3 %) less effective for the hep-
atic patients than for the neurological patients. Note that
the total number of TBs involving patients in different
phenotype groups does not equal the overall effectiveness
Table 1 Characteristics of 17 included studies on combination therapies





Gender Phenotype Data collected
Male Female Nue. Hep. Mixed Asy. From To
23011036 Sini et al. [1] Italy 23.0 60 19 41 0 38 22 0 1981 2011
22055589 El-Karaksy et al. [2] Egypt 10.3 54 31 23 5 33 3 13 1996 2009
22355993 Noureen and Rana [3] Pakistan 9.1 50 34 16 46 0 4 0 2005 2008
21682854 Abdel et al. [4] Egypt 10.0 77 43 34 6 35 9 27 1992 2009
17709362 Sinha et al. [5] India 14.4 50 30 20 39 3 8 0 1999 2002
14759316 Li et al. [6] China 10.0 21 9 12 6 9 6 0 1990 1998
11837754 Sinha et al. [7] India 13.3 49 38 11 27 0 22 0 1991 2000
10869138 Kalra et al. [8] India 7.2 25 14 11 5 7 9 4 1986 1997
10745386 Yu¨ce et al. [9] Turkey 9.0 34 19 15 4 30 0 0 1980 1998
9193846 Schumacher et al. [10] Germany 27.0 13 5 8 4 7 2 0 1988 1995
8076990 Gill et al. [11] India 19.6 11 7 4 0 11 0 0 – –
11819363 Ren et al. [12] China 19.0 120 65 55 – – – – 1994 1997
16606763 Brewer et al. [13] USA – 23 – – 23 0 0 0 – –
17460493 Arnon et al. [14] USA 12.5 22 11 11 0 15 2 0 1998 2006
20958917 Bruha et al. [15] Czech 38.5 117 59 58 21 51 34 11 1965 2008
21185835 Weiss et al. [16] Germany and
Austria
17.5 288 123 165 60 157 39 32 1954 2008
24661374 Ranucci et al. [17] Italy 6.0 42 30 12 0 38 4 0 1984 2012
Total 17.6 1056 537 496 246 434 164 87
Percentage (%) (mean) 52.0 48.0 26.4 46.6 17.6 9.3
PMID PubMed literature ID, Neu. neurological, Hep. hepatic, Asy. asymptomatic or presymptomatic, – not available
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number since some of the studies in the sample did not give
specific statistics for different phenotypes. A comparison of
all phenotypes and combination therapy effectiveness
revealed statistically significant correlations between the
two factors (v2(3) = 26.666, p\ 0.001) (data not shown);
medium–low positive correlations between the two vari-
ables were noted in the form of Cramer’s V value (0.321,
significant at 0.001). In contrast, results from correlation
and difference tests involving various combination therapy
types and overall effectiveness were not statistically sig-
nificant (v2(1) = 0.373, p = 0.541 and Z = -0.611,
p = 0.271). In other words, the data indicate that similar
results are produced by all of the combination therapy
types reviewed for this paper.
3.4 Adverse Effects
Data on combination therapy safety, including adverse
effects and mortality, are presented in Table 4. Since the
first combination therapy type was clearly the most com-
mon, we collapsed the other six to create a workable bal-
ance between sample sizes. Note that we split the statistics
for one study [11] into two parts because the patients were
treated with two different combination therapies. Since
some of the studies in the sample did not specifically
describe adverse reactions for different phenotypes, the
numbers of TBs for different phenotypes and for overall
adverse effects are not equal. Of the 271 TBs listed in
Table 4, 97 resulted in adverse reactions, an overall








95 % CI (%)
RR between combination
therapies and others
On combination therapies (pooled) 437 264 60.4 55.8–65.0 –
On DPA monotherapy [15] 99 73 73.7 65.1–82.4 0.82
On TETA monotherapy [37] 109 90 82.6 75.4–89.7 0.73
On zinc monotherapy [16] 88 63 71.6 62.2–81.0 0.84
TBs treatment blocks, CI confidence interval, RR relative risk ratio, DPA penicillamine, TETA trientine
Fig. 2 Forest plot of 17 included studies measuring relative risk of pooled effectiveness following combination therapy compared to DPA
monotherapy [15]
Fig. 3 Forest plot of 17 included studies measuring relative risk of pooled effectiveness following combination therapy compared to TETA
monotherapy [37]
Fig. 4 Forest plot of 17 included studies measuring relative risk of pooled effectiveness following combination therapy compared to Zn
monotherapy [16]
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Fig. 5 Forest plot of studies on combination therapies for hepatic phenotype versus neurological phenotype examining relative risk of
effectiveness







Neurological Hepatic Mixed Asymptomatic
NA? NA- HA? HA- MA? MA- AA? AA- A? A- Dead LT Alive Mortality
(%)
23011036 a 0 0 13 0.0
22055589 a 1 4 10 23 1 2 12 29 8 3 30 26.8
22355993 a 0 0 50 0.0
21682854 a 4 0 18 9 7 1 3 16 32 26 16 0 42 27.6
17709362 a 0 0 50 0.0
14759316 a 4 14 5 0 13 27.8
11837754 a – – – –
10869138 a 1 0 19 5.0
10745386 a 0 4 7 15 7 19 4 3 19 26.9
9193846 a 0 6 0 100.0
8076990 a 1 0 5 16.7
Subtotal 5 8 35 47 8 3 3 16 55 88 35 12 241 16.3
Percentage (%) 38.5 61.5 42.7 57.3 72.7 27.3 15.8 84.2 38.5 61.5 12.2 4.2 83.7
8076990 c 1 0 2 33.3
11819363 b 22 38 0 0 60 0.0
16606763 e 5 18 5 18 4 0 19 17.4
17460493 d 0 2 0 2 0 0 2 0.0
20958917 b 0 2 0 2 – – – –
21185835 f 10 20 0 1 29 3.3
24661374 b 5 6 0 0 11 0.0
Subtotal 5 20 0 2 0 0 0 0 42 86 5 1 123 4.7
Percentage (%) 20.0 80.0 0.0 100 – – – – 32.8 67.2 3.9 0.8 95.3
Total 10 28 35 49 8 3 3 16 97 174 40 13 364 12.7
Percentage (%) 26.3 73.7 41.7 58.3 72.7 27.3 15.8 84.2 35.8 64.2 9.6 3.1 87.3
Comb. type combination therapy type, A? adverse effect, A- non-adverse effect, – not available, LT liver transplantation, Alive LT excluded,
Mortality (Dead ? LT)/(Dead ? LT ? Alive)
Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease 703
123
adverse effect rate of 35.8 % (95 % CI 30.1–41.5 %). The
percentage for patients in the hepatic category was 41.7 %
(95 % CI 31.1–52.2 %) and that for those in the neuro-
logical category was 26.3 % (95 % CI 12.3–40.3 %), not
significantly different (p = 0.84), perhaps due to the small
sample size. Results from our analysis of inter-studies on
adverse effect rates are presented in Fig. 6, with the
number of events noted as the number of TBs presenting
adverse effects. The data indicate that the combination
therapies resulted in greater relative risk compared to those
for the TETA (RR: 1.67, 95 % CI 1.04–2.69) and Zn (RR:
2.25, 95 % CI 1.36–3.73) monotherapies [16], but not that
for the DPA monotherapy [37] (RR: 1.10, 95 % CI
0.87–1.38). Statistically significant differences were not
noted for correlation and difference measures between
different combination therapy types and overall adverse
effects (v2(1) = 0.938, p = 0.333 and Z = -0.968,
p = 0.166).
3.5 Mortality
Detailed mortality data associated with combination ther-
apy studies are presented along the right-hand side of
Table 4. Pooled results from mortality investigations of the
four most commonly used medications (DPA, TETA and
Zn monotherapies, and combination therapy) and from
studies of the combination therapies alone are presented in
Table 5. As shown, of the 2239 patients mentioned in 44 of
the 50 studies of the four most common medications, 103
died and 44 received liver transplants, a mortality rate of
6.6 % (95 % CI 5.5–7.6 %). In contrast, the mortality rate
for all patients receiving some form of combination therapy
was 12.7 % (95 % CI 9.5–15.9 %), suggesting that those
therapies failed to help a large number of individuals with
acute WD. For this part of our analysis, we used the
number of deceased and liver transplant patients as the
number of events. A statistically significant difference was
found between mortality rates for patients receiving com-
bination therapies and those receiving common medica-
tions (Fig. 7; RR: 1.94, p\ 0.001). Since we did not
measure the percentages of patients who experienced acute
liver failure, the two group analyses may suffer from bias.
Still, the pooled data suggest that combination therapy
patients had a much higher mortality rate compared to
those receiving the other frequently used medications.
Mortality rates for patients in different phenotype
groups were difficult to determine due to the small sample
size and lack of mortality data for each group. However,
Fig. 6 Forest plot of 17 included studies measuring relative risk of pooled adverse effects following combination therapy compared to a DPA,
b TETA, and c Zn monotherapies
Table 5 Mortality statistics for different patient groups in included studies
No. of patients (%) Dead LT Alive Mortality (%) Patients in total Studies included
On common medications (pooled) 103 (4.6 %) 44 (2.0 %) 2092 (93.4 %) 6.6 2239 44 of 50
On combination therapies (pooled) 40 (9.6 %) 13 (3.1 %) 364 (87.3 %) 12.7 417 15 of 17
LT liver transplantation, Mortality (Dead ? LT)/(Patients in total)
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we did find statistically significant differences in mortality
among patients receiving different types of combination
therapies (p\ 0.001). Patients in the DPA ? Zn sulfate
group had a much higher mortality rate compared to those
in all other groups (16.3 vs. 4.7 %; RR: 3.51, 95 % CI
1.54–8.00). Chi square test results indicate a statistically
significant correlation (v2(1) = 10.933; p = 0.001)
between combination therapy type and mortality.
4 Discussion
In light of the rarity of WD cases and lack of clinical
consensus on the best medications, our goal was to sys-
tematically review the literature and to perform statistical
analyses to support or refute assertions of the success of
various combination therapies. Our results indicate a suc-
cess rate for combination therapies of approximately 60 %,
much lower than expected. That figure is significantly less
than those reported by Bruha et al. for DPA monotherapy
(73.7 %) [15], Weiss et al. for TETA monotherapy
(82.6 %) [37], and Weiss et al. for zinc monotherapy
(71.6 %) [16]. We found strong evidence indicating that
hepatic patients do not respond well to combination ther-
apies, with a reported effectiveness rate of 47.1 versus
78.6 % for patients with neurological manifestations.
Results from a pooled analysis show that compared to
hepatic manifestation patients, neurological patients were
significantly more likely to receive benefits from combi-
nation therapies. For example, Pellecchia et al. [38] found
that DPA combined with zinc is effective and safe for
neurologically impaired patients. In terms of safety, the
studies we reviewed reported a 35.8 % pooled adverse
effect for all patients receiving some type of combination
therapy (41.7 % for hepatic patients and 26.3 % for
patients with neurological presentations). The lack of a
statistically significant difference between the two pheno-
types is likely due to the small sample size, yet there is still
potential for clinical significance. Regarding mortality
associated with combination therapies, the 12.7 % rate was
significantly higher than the 6.6 % rate reported for com-
mon medication therapies. It is likely that the mortality rate
is higher for hepatic patients, but the reviewed studies did
not contain specific mortality data for that group. One
unexpected finding was the higher mortality rate for
patients receiving DPA plus zinc sulfate compared to other
types of combination therapies (16.3 vs. 4.7 %). Thus,
Yonetani and Walshe [34] emphasize the danger of using
zinc sulfate with any chelation regimen.
From our analysis, it appears that the literature lacks
rigorously designed studies and safety data on combination
therapies using zinc and a chelator. The three most fre-
quently cited studies that suggest favorable outcomes for
combination therapies involving zinc plus either DPA or
TETA are those by Dhawan et al. [30], Askari et al. [31],
and Santos Silva et al. [32]. Dhawan et al.’s research focus
was the scoring system for WD liver transplants [30], but in
their report they claim that 20 symptomatic, non-deceased,
and non-liver-transplant-receiving children did not require
transplants for a long period of time after receiving a
combination of DPA plus zinc. Their study is lacking in
several respects: it does not include detailed evaluations
regarding the clinical effectiveness of combination therapy,
nor do they provide follow-up information for seven
asymptomatic siblings who were treated with a combina-
tion of DPA and zinc. In their paper, Askari et al. [31]
described the successful use of TETA plus zinc in eight
patients with decompensated hepatic WD, but their
approach involved the use of that combination therapy for
4 months, followed by a regimen of zinc monotherapy.
They claim that the combination therapy reduced or
eliminated the need for liver transplants, but the time
period involved was imprecise. Santos Silva et al. [32]
evaluated the effectiveness of DPA plus zinc for treatment
periods ranging from one to 2 years, but some of the
patients in their study had to be shifted to other therapies
due to the adverse effects of the initial combination ther-
apy. They mention three combination therapy patients
during an initial follow-up period and four during a second
follow-up period, but they are unclear about overlaps.
Some researchers [33, 34] have argued that there is no
advantage to the concomitant administration of DPA and
zinc, suggesting that zinc may interact with both DPA and
TETA, and possibly inhibit chelator absorption and action
[33, 39]. A third research team has made the strong rec-
ommendation that zinc sulfate should never be used with
chelation medication [34]. Friedman and Yarze [40] also
argue that it is counterproductive to use a combination of
chelators and zinc in WD patients. According to EASL
guidelines [19], there are no known advantages to using
Fig. 7 Forest plot of 17 included studies measuring relative risk of pooled mortality following combination therapy compared to pooled
mortality of four most commonly used medications
Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease 705
123
combination therapies involving a chelator and zinc,
though they do not deny the possibility. AASLD guidelines
[20] are unclear on this question, simply stating a need for
more confirmatory research.
In one retrospective cohort study [16], six combination
therapy TBs were discontinued because the physician
suspected that the zinc and chelator were interacting
pharmacologically. Arnon et al. [14] reported that two
patients taking TETA monotherapy alone for 6 months had
their hepatic alanine aminotransferase (ALT) levels return
to normal. The decision was made to switch to a combi-
nation of TETA plus zinc, but after another 6 months their
ALT levels nearly doubled, and after a full year they were
almost three times the level considered normal [14]. The
authors speculated that the patients may not have been
adherent, but this idea was neither tested nor verified. They
did, however, suggest that future combination therapy was
unnecessary.
The literature contains other evidence concerning
chelator-zinc interaction. In their study of urinary copper
excretion following TETA monotherapy, Dubois et al. [41]
reported that urinary zinc content increased from 181
lg/day pre-treatment to 402 lg/day post-treatment. Their
observations were similar to those reported by McCall
et al. [42] in a metabolic study involving DPA trials.
Kodama et al. [43] reported a significant increase in the
urinary excretion of zinc in a group of healthy (non-WD)
volunteers during the first 6 hours following TETA
administration. Kuchinskas and Rosen [39] investigated the
affinities of bivalent metals for DPA, and reported a high-
to-low affinity order of Hg[Ni[Cu[Zn[Cd[Pb;
this serves as indirect evidence that DPA is capable of
chelating both copper and zinc. Cossack and Bouquet [44]
have described a sub-clinical deficiency of zinc induced by
DPA treatment. In an animal study [45], Fieten et al.
evaluated hepatic copper and zinc concentrations before
and after DPA monotherapy treatment in 42 Labrador
Retrievers, and reported significant decreases in both
concentrations in the dogs’ livers. Combined, these studies
suggest that zinc should not be combined with a chelator,
even several hours apart, because doing so is likely to
reduce the effectiveness of zinc for treating WD. Further,
the existing evidence indicates that the presence of zinc in
the bloodstream and gut may alter the effect of chelators on
copper.
5 Conclusion
Our main findings are (a) an overall effectiveness rate of
only 47.1 % and (b) an overall adverse effect rate of
41.7 % among hepatic patients treated with combination
therapies. We also found that the overall mortality rate for
patients receiving a combination therapy was 12.7 %,
double that reported for patients receiving the four most
commonly used medications. Another important finding is
that the combination therapy of DPA plus zinc sulfate
resulted in much higher mortality rates compared to those
for all other combination therapy types (16.3 vs. 4.7 %).
However, the pooled data cannot be considered high-
quality evidence for estimating the effectiveness and safety
of combination therapies. Thus, these findings should be
used to support treatment decisions only until more and
higher-quality evidence becomes available. More large-
cohort randomized clinical trials and/or evidence-based
studies are still required to fully address the issues men-
tioned in this review. Our primary conclusion is that clin-
icians should closely monitor biochemical test results and
clinical courses for WD patients receiving combination
therapies, especially in response to hepatic manifestations.
6 Limitations
Possible limitations to our findings include a lack of
stratification for mild, moderate, and severe adverse
effects, plus the apparent lack of high-quality evidence in
support of estimates of relative effectiveness and adverse
effects of combination therapies versus monotherapies.
Further, there may be bias in some interpretations of results
due to the lack of substantial data and additional reports on
combination therapies. For these reasons, no firm recom-
mendations can be drawn from the pooled data. Note also
that WD is an intractable disease, meaning that individual
patients may have different responses to each of the four
most commonly used medications due to variance in WD
genotypes and phenotypes. Consequently, neither a stan-
dard treatment regimen nor a clear consensus exists
regarding an optimal medication therapy for treating the
disease. More evidence-based studies and/or large-cohort
randomized controlled comparative trials are required.
Acknowledgments The authors gratefully acknowledge the finan-
cial support from the Taiwan Ministry of Science and Technology
(NSC 102-2221-E-468-010- and MOST 103-2221-E-468-002-).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Sini, M., Sorbello, O., Sanna, F., Battolu, F., Civolani, A., Fanni,
D., et al. (2013). Histologic evolution and long-term outcome of
706 J.-C. Chen et al.
123
Wilson’s disease: Results of a single-center experience. Euro-
pean Journal of Gastroenterology and Hepatology, 25,
111–117.
2. El-Karaksy, H., Fahmy, M., El-Raziky, M. S., El-Hawary, M., El-
Sayed, R., El-Koofy, N., et al. (2011). A clinical study of Wilson’s
disease: The experience of a single Egyptian Paediatric Hepatology
Unit. Arab Journal of Gastroenterology, 12, 125–130.
3. Noureen, N., & Rana, M. T. (2011). Neurological Wilson disease
in children: A three years experience from Multan. Journal of the
Pakistan Medical Association, 61, 743–748.
4. Abdel Ghaffar, T. Y., Elsayed, S. M., Elnaghy, S., Shadeed, A.,
Elsobky, E. S., & Schmidt, H. (2011). Phenotypic and genetic
characterization of a cohort of pediatric Wilson disease patients.
BMC Pediatrics, 11(1), 56.
5. Sinha, S., Taly, A. B., Prashanth, L. K., Ravishankar, S., Arun-
odaya, G. R., & Vasudev, M. K. (2007). Sequential MRI changes
in Wilson’s disease with de-coppering therapy: A study of 50
patients. British Journal of Radiology, 80, 744–749.
6. Li, M., Zhang, Y. H., & Qin, J. (2003). Treatment of Wilson’s
disease with penicillamine and zinc salts: A follow-up study.
Chinese Journal of Pediatrics, 41, 119–122.
7. Sinha, S., Jha, D. K., & Sinha, K. K. (2001). Wilson’s disease in
Eastern India. Journal of the Association of Physicians of India,
49, 881–884.
8. Kalra, V., Khurana, D., & Mittal, R. (2000). Wilson’s disease-
early onset and lessons from a pediatric cohort in India. Indian
Pediatrics, 37, 595–601.
9. Yu¨ce, A., Kocak, N., Gu¨rakan, F., & Ozen, H. (2000). Wilson’s
disease with hepatic presentation in childhood. Indian Pediatrics,
37, 31–36.
10. Schumacher, G., Platz, K. P., Mueller, A. R., Neuhaus, R., Stein-
mu¨ller, T., Bechstein, W. O., et al. (1997). Liver transplantation:
Treatment of choice for hepatic and neurological manifestation of
Wilson’s disease. Clinical Transplantation, 11, 217–224.
11. Gill, H. H., Shankaran, K., & Desai, H. G. (1994). Wilson’s
disease: Varied hepatic presentations. Indian Journal of Gas-
troenterology, 13, 95–98.
12. Ren, M. S., Zhang, Z., Wu, J. X., Li, F., Xue, B. C., & Yang, R.
M. (1998). Comparison of long lasting therapeutic effects
between succimer and penicillamine on hepatolenticular degen-
eration. World Journal of Gastroenterology, 4, 530–532.
13. Brewer, G. J., Askari, F., Lorincz, M. T., Carlson, M., Schilsky,
M., Kluin, K. J., et al. (2006). Treatment of Wilson disease with
ammonium tetrathiomolybdate: IV. Comparison of
tetrathiomolybdate and trientine in a double-blind study of
treatment of the neurologic presentation of Wilson disease.
Archives of Neurology, 63, 521–527.
14. Arnon, R., Calderon, J. F., Schilsky, M., Emre, S., & Shneider, B.
L. (2007). Wilson disease in children: Serum aminotransferases
and urinary copper on triethylene tetramine dihydrochloride
(trientine) treatment. Journal of Pediatric Gastroenterology and
Nutrition, 44, 596–602.
15. Bruha, R., Marecek, Z., Pospisilova, L., Nevsimalova, S., Vitek,
L., Martasek, P., et al. (2011). Long-term follow-up of Wilson
disease: Natural history, treatment, mutations analysis and phe-
notypic correlation. Liver International, 31, 83–91.
16. Weiss, K. H., Gotthardt, D. N., Klemm, D., Merle, U., Ferenci-
Foerster, D., Schaefer, M., et al. (2011). Zinc monotherapy is not
as effective as chelating agents in treatment of Wilson disease.
Gastroenterology, 140, 1189–1198.
17. Ranucci, G., Di Dato, F., Spagnuolo, M. I., Vajro, P., & Iorio, R.
(2014). Zinc monotherapy is effective in Wilson’s disease
patients with mild liver disease diagnosed in childhood: A ret-
rospective study. Orphanet Journal of Rare Diseases, 9, 41.
18. Frydman, M. (1990). Genetic aspects of Wilson’s disease. Jour-
nal of Gastroenterology and Hepatology, 5, 483–490.
19. Ferenci, P., Czlonkowska, A., Stremmel, W., Houwen, R.,
Rosenberg, W., & Schilsky, M. (2012). European Association for
the Study of the Liver (EASL). Clinical Practice Guidelines:
Wilson’s disease. Journal of Hepatology, 56, 671–685.
20. Roberts, E. A., & Schilsky, M. L. (2008). American Association
for Study of Liver Diseases (AASLD). Diagnosis and treatment
of Wilson disease: An update. Hepatology, 47, 2089–2111.
21. Youn, J., Kim, J. S., Kim, H. T., Lee, J. Y., Lee, P. H., Ki, C. S.,
& Cho, J. W. (2012). Characteristics of neurological Wilson’s
disease without Kayser–Fleischer ring. Journal of the Neuro-
logical Sciences, 323, 183–186.
22. Walshe, J. M. (1956). Penicillamine, a new oral therapy for
Wilson’s disease. American Journal of Medicine, 21, 487–495.
23. Walshe, J. M. (1969). Management of penicillamine nephropathy
in Wilson’s disease: A new chelating agent. Lancet, 2, 1401–1402.
24. Walshe, J. M. (2005). Hepatic Wilson’s disease: Initial treatment
and long-term management. Current Treatment Options in Gas-
troenterology, 8, 467–472.
25. Hoogenraad, T. U., Van Hattum, J., & Van den Hamer, C. J.
(1987). Management of Wilson’s disease with zinc sulphate:
Experience in a series of 27 patients. Journal of the Neurological
Sciences, 77, 137–146.
26. Walshe, J. M. (1984). Copper: Its role in the pathogenesis of liver
disease. Seminars in Liver Disease, 4, 252–263.
27. Brewer, G. J., Hedera, P., Kluin, K. J., Carlson, M., Askari, F.,
Dick, R. B., et al. (2003). Treatment of Wilson disease with
ammonium tetrathiomolybdate: III. Initial therapy in a total of 55
neurologically affected patients and follow-up with zinc therapy.
Archives of Neurology, 60, 379–385.
28. Wiggelinkhuizen, M., Tilanus, M. E., Bollen, C. W., & Houwen,
R. H. (2009). Systematic review: Clinical efficacy of chelator
agents and zinc in the initial treatment of Wilson disease. Ali-
mentary Pharmacology & Therapeutics, 29, 947–958.
29. Weiss, K. H., & Stremmel, W. (2012). Evolving perspectives in
Wilson disease: Diagnosis, treatment and monitoring. Current
Gastroenterology Reports, 14, 1–7.
30. Dhawan, A., Taylor, R. M., Cheeseman, P., De Silva, P., Kat-
siyiannakis, L., & Mieli-Vergani, G. (2005). Wilson’s disease in
children: 37-year experience and revised King’s score for liver
transplantation. Liver Transplantation, 11, 441–448.
31. Askari, F. K., Greenson, J., Dick, R. D., Johnson, V. D., &
Brewer, G. J. (2003). Treatment of Wilson’s disease with zinc.
XVIII. Initial treatment of the hepatic decompensation presen-
tation with trientine and zinc. Journal of Laboratory and Clinical
Medicine, 142, 385–390.
32. Santos Silva, E. E., Sarles, J., Buts, J. P., & Sokal, E. M. (1996).
Successful medical treatment of severely decompensated Wilson
disease. The Journal of Pediatrics, 128, 285–287.
33. Brewer, G. J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R. D.,
& Wang, Y. (1993). Treatment of Wilson’s disease with zinc: XI.
Interaction with other anticopper agents. Journal of the American
College of Nutrition, 12, 26–30.
34. Yonetani, L., & Walshe, J. M. (2001). Surviving Wilson’s dis-
ease. Clinical Medicine, 1, 72–74.
35. National Center for Biotechnology Information, U.S. National
Library of Medicine, USA. http://www.ncbi.nlm.nih.gov/
PubMed/. Database PubMed, 2014.
36. Ferenci, P., Caca, K., Loudianos, G., Mieli-Vergani, G., Tanner,
S., Sternlieb, I., et al. (2003). Diagnosis and phenotypic classi-
fication of Wilson disease. Liver International, 23, 139–142.
37. Weiss, K. H., Thurik, F., Gotthardt, D. N., Scha¨fer, M., Teufel,
U., Wiegand, F., et al. (2013). Efficacy and safety of oral
chelators in treatment of patients with Wilson disease. Clinical
Gastroenterology and Hepatology, 11, 1028–1035.
38. Pellecchia, M. T., Criscuolo, C., Longo, K., Campanella, G.,
Filla, A., & Barone, P. (2003). Clinical presentation and
Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease 707
123
treatment of Wilson’s disease: A single-centre experience.
European Neurology, 50, 48–52.
39. Kuchinskas, E. J., & Rosen, Y. (1962). Metal chelates of DL-
penicillamine. Archives of Biochemistry and Biophysics, 97, 370.
40. Friedman, L. S., & Yarze, J. C. (1993). Zinc in the treatment of
Wilson’s disease: How it works. Gastroenterology, 104,
1566–1568.
41. Dubois, R. S., Rodgerson, D. O., & Hambidge, K. M. (1990).
Treatment of Wilson’s disease with triethylene tetramine
hydrochloride (Trientine). Journal of Pediatric Gastroenterology
and Nutrition, 10, 77–81.
42. McCall, J. T., Goldstein, N. P., Randall, R. V., & Gross, J. B.
(1967). Comparative metabolism of copper and zinc in patients
with Wilson’s disease (hepatolenticular degeneration). American
Journal of the Medical Sciences, 254, 13–23.
43. Kodama, H., Murata, Y., Iitsuka, T., & Abe, T. (1997). Meta-
bolism of administered triethylene tetramine dihydrochloride in
humans. Life Sciences, 61, 899–907.
44. Cossack, Z. T., & Bouquet, J. (1986). The treatment of Wilson’s
disease in paediatrics: Oral zinc therapy versus penicillamine.
Acta Pharmacologica et Toxicologica, 59, 514–517.
45. Fieten, H., Dirksen, K., van den Ingh, T. S., Winter, E. A.,
Watson, A. L., Leegwater, P. A., & Rothuizen, J. (2013).
d-penicillamine treatment of copper-associated hepatitis in Lab-
rador retrievers. The Veterinary Journal, 196, 522–527.
708 J.-C. Chen et al.
123
